Actavis plc has rolled out a clonidine transdermal system, a patch-based treatment for high blood pressure.


Actavis, generic version of Catapres-TTS, clonidine transdermal system, clonidine patch, Boehringer Ingelheim, hypertension, high blood pressure












































































































































































































































INSIDE THIS ISSUE
News
Opinion
Other Services
Reprints / E-Prints
Submit News
White Papers

Supplier News Breaks Archives

Actavis releases Catapres-TTS generic

May 7th, 2014

DUBLIN, Ireland – Actavis plc has rolled out a clonidine transdermal system, a patch-based treatment for high blood pressure.

The company said Wednesday that its clonidine patch (0.1 mg/day, 0.2 mg/day and 0.3 mg/day for one week) is a generic version of Catapres-TTS from Boehringer Ingelheim.

Catapres-TTS is a transdermal therapeutic system indicated for the treatment of hypertension. Clonidine reduces blood pressure by decreasing the levels of certain chemicals in the blood. The patch can be used with other blood pressure medications.

For the 12 months ended Feb. 28, Catapres-TTS had U.S. sales of approximately $180 million, according to IMS Health data reported by Actavis.

Advertisement